Formulary guidance and transparency from P&T to point of care


Reality Check on Migraine

Market access for migraine treatments reveals differences in payer coverage across each major channel, as well as specific trends in the drug landscape.  

To help make sense of this new research, MMIT's team of experts has analyzed the data for you and summarized the key findings:

  • Payer Insights: About 42% of the covered lives under commercial formularies are restricted
  • Class Trends: The FDA in September approved two new migraine drugs: Eli Lilly and Co.'s Emgality and Teva Pharmaceuticals' Ajovy
  • Key Findings: The launch of the CGRP inhibitors disrupts the current market dynamics, and it's currently unclear if they will create a treatment step after generic products but before botulinum toxins or be treated roughly equal to botulinum toxins 

What can pharma do to curb this trend and overcome these challenges?

Get the data behind this change and how it could impact your market access plans from MMIT's team. Their clinical and policy backgrounds provide a unique and expert perspective to help expand your knowledge in the class and guide your decision-making process.

Download the full Reality Check now.